All In MedTech

Device Trial Radar · NCT07914621

Outpatient Pramlintide Study

An Outpatient Crossover Study to Evaluate Insulin and Pramlintide Versus Insulin Alone Delivery Strategy

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Oregon Health and Science UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Nov 3, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Health services research
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the performance of a dual-hormone automated insulin delivery (AID) system that delivers both insulin and pramlintide with an AID that only delivers insulin. Our hypothesis is that people using the dual-hormone AID will have a significantly increased percent time in range (70-180 mg/dL) compared with when they use a single-hormone insulin-only AID. Both systems are designed to automatically dose meal insulin if the participant forgets to enter their meal insulin at the time of their meals.

Conditions

  • Type 1 Diabetes

Interventions

  • Single-hormone automated insulin delivery systemDevice

    The intervention in this arm is a single-hormone automated insulin delivery system that delivers insulin in response to sensed continuous glucose monitoring data (CGM) received from a Dexcom G6 CGM. The system automatically detects meals and delivers meal insulin based on the detected meal size. Users of the system have the option to use a bolus calculator to dose meal insulin in advance of their meals if they choose. The AID also automatically detects exercise and adjusts insulin based on increased levels of physical activity. The system comprises an Android Pixel smart phone running the AID control algorithm, a Dexcom G6 sensor, an Insulet Omnipod Dash pump, and an Android Pixel smart watch to quantify exercise.

  • Dual-hormone automated insulin and pramlintide delivery systemDevice

    The intervention in this arm is a dual-hormone automated insulin and pramlintide delivery system that delivers insulin and pramlintide in response to sensed continuous glucose monitoring data (CGM) received from a Dexcom G6 CGM. Insulin and pramlintide are delivered in a fixed ratio of 1 u insulin: 6 mcg pramlintide. The system automatically detects meals and delivers meal insulin and pramlintide based on the detected meal size. Users of the system have the option to use a bolus calculator to dose meal insulin and pramlintide in advance of their meals if they choose. The system also automatically detects exercise and adjusts insulin based on increased levels of physical activity. The system comprises an Android Pixel smart phone running the AID control algorithm, a Dexcom G6 sensor, an Insulet Omnipod Dash pump filled with insulin, a Dash pump filled with pramlintide, and an Android Pixel smart watch to quantify exercise.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of time with sensed glucose between 70-180 mg/dl during the daytimeTime frame: CGM measured during the daytime (06:00-23:59) hours for all days in the week when participants used the single-hormone system compared with all days in the week when participants used the dual-hormone system.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.